Screening neuromyelitis optica patients for COVID-19 infection

(2020) Screening neuromyelitis optica patients for COVID-19 infection. Autoimmunity Reviews. ISSN 1568-9972

Full text not available from this repository.

Abstract

Dear editor, Nowadays, SARS CoV 2 a new coronavirus with high infect ability, is in pandemic stage and most countries all over the world are involved [1]. Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system (CNS) affecting women more than men [2]. Treatment options include immuno-suppressive agents which may predispose patients to the wide range of infections such as COVID-19. So, careful monitoring of NMO patients is essential and neurologists have to pay attention to these cases such as other patients with autoimmune diseases like Multiple sclerosis (MS) [3].We designed this study to screen NMO patients for COVID-19 infection during the pandemic stage. The study was performed in accordance with good clinical practice and the Declaration of Helsinki.

Item Type: Article
Keywords: RITUXIMAB
Subjects: WC Communicable Diseases > WC 500-590 Virus Diseases
WL Nervous System
Divisions: Faculty of Medicine > Departments of Clinical Sciences > Department of Neurology
Isfahan Neurosciences Research Center
Journal or Publication Title: Autoimmunity Reviews
Journal Index: ISI
Volume: 19
Number: 11
Identification Number: https://doi.org/10.1016/j.autrev.2020.102669
ISSN: 1568-9972
Depositing User: Zahra Otroj
URI: http://eprints.mui.ac.ir/id/eprint/13139

Actions (login required)

View Item View Item